Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CC-99282 + Mosunetuzumab-axgb |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CC-99282 | CC99282|CC 99282|BMS-986369|BMS986369|BMS 986369|Golcadomide | CC-99282 modulates cereblon E3 ubiquitin ligase, leading to degradation of the transcription factors Ikaros and Aiolos, potentially resulting in decreased tumor cell proliferation, enhanced apoptosis, and antitumor activity (Blood (2021) 138 (Supplement 1). | ||
Mosunetuzumab-axgb | Lunsumio | RG7828|BTCT4465A|RO7030816|BTCT-4465A | CD20 Antibody 24 CD3 Antibody 99 | Lunsumio (mosunetuzumab-axgb) is a bispecific antibody targeting CD20 and CD3, which may result in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372). Lunsumio (mosunetuzumab-axgb) is FDA approved for use in adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05169515 | Phase I | Glofitamab-gxbm + Iberdomide CC-99282 + Glofitamab-gxbm CC-99282 + Mosunetuzumab-axgb Iberdomide + Mosunetuzumab-axgb | A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Recruiting | USA | ITA | ISR | GBR | ESP | 0 |